Oliver McCammon
Stock Analyst at LifeSci Capital
(4.89)
# 333
Out of 4,668 analysts
84
Total ratings
59.4%
Success rate
67.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Oliver McCammon
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CELC Celcuity | Maintained: Buy | $165 | $90.57 | +82.18% | 15 | Aug 14, 2026 | |
| CADL Candel Therapeutics | Maintained: Buy | $16 | $12.35 | +29.55% | 6 | Aug 14, 2026 | |
| INBX Inhibrx Biosciences | Maintained: Buy | $230 | $99.15 | +131.97% | 4 | Aug 14, 2026 | |
| AURA Aura Biosciences | Maintained: Buy | $23 | $7.77 | +196.01% | 10 | Aug 12, 2026 | |
| CATX Perspective Therapeutics | Maintained: Buy | $15 | $3.21 | +367.29% | 11 | Aug 11, 2026 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintained: Buy | $38 | $9.84 | +286.18% | 10 | Aug 7, 2026 | |
| JANX Janux Therapeutics | Maintained: Buy | $60 | $17.28 | +247.22% | 13 | Aug 7, 2026 | |
| GLUE Monte Rosa Therapeutics | Reiterated: Buy | n/a | $14.78 | - | 15 | Aug 6, 2026 |
Celcuity
Aug 14, 2026
Maintained: Buy
Price Target: $165
Current: $90.57
Upside: +82.18%
Candel Therapeutics
Aug 14, 2026
Maintained: Buy
Price Target: $16
Current: $12.35
Upside: +29.55%
Inhibrx Biosciences
Aug 14, 2026
Maintained: Buy
Price Target: $230
Current: $99.15
Upside: +131.97%
Aura Biosciences
Aug 12, 2026
Maintained: Buy
Price Target: $23
Current: $7.77
Upside: +196.01%
Perspective Therapeutics
Aug 11, 2026
Maintained: Buy
Price Target: $15
Current: $3.21
Upside: +367.29%
Corbus Pharmaceuticals Holdings
Aug 7, 2026
Maintained: Buy
Price Target: $38
Current: $9.84
Upside: +286.18%
Janux Therapeutics
Aug 7, 2026
Maintained: Buy
Price Target: $60
Current: $17.28
Upside: +247.22%
Monte Rosa Therapeutics
Aug 6, 2026
Reiterated: Buy
Price Target: n/a
Current: $14.78
Upside: -